Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America AVDL
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America RNA
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America AYTU
Azitra, Inc. Logo
Developing engineered proteins and live biotherapeutics for rare skin diseases.
United States of America AZTR
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland BANB
Barinthus Biotherapeutics plc. Logo
Develops T cell immunotherapies for autoimmune and chronic infectious diseases.
United States of America BRNS
Basilea Pharmaceutica AG Logo
Develops & commercializes anti-infectives for severe bacterial & fungal infections.
Switzerland BSLN
Bausch Health Companies Inc. Logo
Develops, manufactures, and markets pharmaceuticals, OTCs, and medical devices globally.
United States of America BHC
Bavarian Nordic Logo
A biotech firm developing and manufacturing life-saving vaccines for travel and public health.
Denmark BAVA

Talk to a Data Expert

Have a question? We'll get back to you promptly.